Atlanta, Georgia — October 7, 2025 — Leads & Copy — GeoVax Labs, Inc. (Nasdaq: GOVX) announced that Chairman and CEO David Dodd will participate in the 4th Annual ROTH Healthcare Opportunities Conference on Thursday, October 9, 2025, at the Yale Club in New York City.
The ROTH Healthcare Opportunities Conference is an invite-only event connecting healthcare companies with institutional investors through 1-on-1 and small group meetings, and themed panel discussions. C-level executives in Biotechnology, Medical Technologies, and Pharmaceuticals will share their stories with investors.
The 25-minute management–investor meetings provide ROTH’s institutional clients with opportunities for interaction with executive management teams, delivering insights into each company’s strategy, pipeline, and milestones.
Dodd will be available to meet with investors and discuss GeoVax’s pipeline progress, including GEO-MVA, an MVA-based Mpox/smallpox vaccine; GEO-CM04S1, a multi-antigen COVID-19 vaccine in Phase 2 clinical trials; and Gedeptin®, a gene-directed enzyme prodrug therapy for solid tumors, with a planned Phase 2 trial in head and neck cancer. Investors seeking to schedule a meeting with GeoVax leadership should contact their ROTH representative.
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing vaccines against infectious diseases and therapies for solid tumor cancers. Its lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine in three Phase 2 clinical trials. In oncology, the lead clinical program is evaluating Gedeptin®, having recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax anticipates progressing directly to a Phase 3 clinical evaluation for a vaccine targeting Mpox and smallpox.
Contact: David Dodd, Chairman & CEO
Company Contact: info@geovax.com, 678-384-7220
Media Contact: Jessica Starman, media@geovax.com
Source: GeoVax Labs, Inc.
